Hemostemix Inc. (CVE:HEM – Get Free Report) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as C$0.12 and last traded at C$0.12, with a volume of 60720 shares changing hands. The stock had previously closed at C$0.13.
Hemostemix Trading Up 38.1 %
The company’s 50 day moving average is C$0.09 and its 200-day moving average is C$0.07. The stock has a market cap of C$12.63 million, a PE ratio of -7.25 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Learn Technical Analysis Skills to Master the Stock Market
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Best Stocks Under $10.00
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Basic Materials Stocks Investing
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
